Arcutis Biotherapeutics Inc’s recent filing unveils that its insider Watanabe Todd Franklin unloaded Company’s shares for reported $0.23 million on Dec 20 ’24. In the deal valued at $15.17 per share,15,000 shares were sold. As a result of this transaction, Watanabe Todd Franklin now holds 823,430 shares worth roughly $11.78 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Watanabe Todd Franklin bought 15,000 shares, generating $227,567 in total proceeds.
Before that, Edwards Larry Todd bought 1,093 shares. Arcutis Biotherapeutics Inc shares valued at $7,767 were divested by the insider at a price of $7.11 per share. As a result of the transaction, Edwards Larry Todd now holds 137,728 shares, worth roughly $1.97 million.
Jefferies initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on August 28, 2024; the price target was $15. A number of analysts have revised their coverage, including Mizuho’s analysts, who increased its forecast for the stock in early January from “a Neutral” to “a Buy”. Mizuho also remained covering ARQT and has decreased its forecast on October 26, 2023 with a “Neutral” recommendation from previously “Buy” rating. Goldman revised its rating on October 13, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Friday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock fall -4.22% to $14.30. Over the last five days, the stock has gained 1.35%. Arcutis Biotherapeutics Inc shares have risen nearly 342.72% since the year began. Nevertheless, the stocks have risen 373.51% over the past one year. While a 52-week high of $15.79 was reached on 12/20/24, a 52-week low of $2.96 was recorded on 01/02/24. SMA at 50 days reached $11.11, while 200 days put it at $9.92.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 13.99, which if violated will result in even more drops to 13.67. On the upside, there is a resistance level at 14.82. A further resistance level may holdings at 15.34. The Relative Strength Index (RSI) on the 14-day chart is 60.67, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.91, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.05%. Stochastics %K at 71.77% indicates the stock is a holding.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2024-12-13, dropping by -1.9 million shares to a total of 23.11 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 25.02 million shares. There was a decline of -8.24%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 07, 2022 when Needham began covering the stock and recommended ‘”a Buy”‘ rating along with a $46 price target.
